Compare MNPR & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNPR | TCPC |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 354.1M |
| IPO Year | 2019 | 2006 |
| Metric | MNPR | TCPC |
|---|---|---|
| Price | $62.74 | $3.76 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 11 | 2 |
| Target Price | ★ $107.00 | $3.50 |
| AVG Volume (30 Days) | 164.9K | ★ 610.2K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 18.23% |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.40 | $3.43 |
| 52 Week High | $105.00 | $8.05 |
| Indicator | MNPR | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 33.48 |
| Support Level | $51.71 | $3.43 |
| Resistance Level | $67.90 | $3.75 |
| Average True Range (ATR) | 5.65 | 0.14 |
| MACD | 0.27 | -0.07 |
| Stochastic Oscillator | 68.24 | 8.67 |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.